<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817830</url>
  </required_header>
  <id_info>
    <org_study_id>CRIST001</org_study_id>
    <nct_id>NCT00817830</nct_id>
  </id_info>
  <brief_title>Cardiovascular Safety Study of Lodenafil Carbonate in Patients With Coronaropathy During Physical Effort</brief_title>
  <official_title>Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristália Produtos Químicos Farmacêuticos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cristália Produtos Químicos Farmacêuticos Ltda.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of lodenafil carbonate in patients with&#xD;
      coronaropathy, evaluating the response of the body facing physical effort, including both&#xD;
      heart and respiratory components, with and without use of lodenafil carbonate 80mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phosphodiesterase 5 inhibitors (iPDE5) are effective drugs to treat erectile dysfunction&#xD;
      (ED).&#xD;
&#xD;
      ED is linked to several factors, like advanced age and diabetes as predominant in its&#xD;
      incidence. In addition, ED can be an early manifestation of cardiovascular diseases.&#xD;
&#xD;
      Among the iPDE5 existing in the Brazilian market there is a new molecule which called&#xD;
      lodenafil carbonate. It was recently approve and release for use in Brazil, and has similar&#xD;
      effectiveness and adverse reactions comparing with other drugs from the same family.&#xD;
&#xD;
      The molecule was evaluated with respect to possible changes in heart rate, blood pressure and&#xD;
      QT interval, and the results point out excellent cardiovascular safety profile.&#xD;
&#xD;
      There is a corelated incidence between patients with coronary artery disease and erectile&#xD;
      dysfunction. Although patients with stable angina and, under appropriate clinical treatment&#xD;
      did not show increase in cardiovascular risks during sexual intercourse, the increased&#xD;
      incidence of erectile dysfunction in this population determines a specific group of patients&#xD;
      with high potential for use iPDE5.&#xD;
&#xD;
      Therefore it is essential that any new phosphodiesterase 5 inhibitors should be evaluated in&#xD;
      patients with coronary artery disease, especially in heart rate, during physical effort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficulty in patient recruitment&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date>October 2009</completion_date>
  <primary_completion_date>May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate changes in effort test showing the safety of lodenafil carbonate in patients with coronaropathy.</measure>
    <time_frame>july 2009</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Coronaropathy</condition>
  <arm_group>
    <arm_group_label>lodenafil carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lodenafil carbonate</intervention_name>
    <description>Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.</description>
    <arm_group_label>lodenafil carbonate</arm_group_label>
    <other_name>Helleva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Coronary artery disease with obstruction &lt;70%, confirmed by prior catheterization,&#xD;
             stable patient, and have already showed an acute event (unstable angina or myocardial&#xD;
             infarction, according to the guidelines of the Brazilian Society of Cardiology) for at&#xD;
             least 6 months;&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 60;&#xD;
&#xD;
          -  Men;&#xD;
&#xD;
          -  Stable for 6 months, regardless of previous myocardial infarction or&#xD;
             revascularization;&#xD;
&#xD;
          -  ejection fraction of doppler echocardiography ≥ 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of nitrate;&#xD;
&#xD;
          -  Use of bronchodilators;&#xD;
&#xD;
          -  Smoking current period or in less than 6 months;&#xD;
&#xD;
          -  Hemoglobin &lt;10 g / dL;&#xD;
&#xD;
          -  Systolic pressure&gt; 160 mm Hg and &lt;100 mmHg;&#xD;
&#xD;
          -  Diastolic pressure&gt; 110 mm Hg and &lt;60 mmHg;&#xD;
&#xD;
          -  Body mass index (BMI)&gt; 30;&#xD;
&#xD;
          -  Symptomatic peripheral artery disease;&#xD;
&#xD;
          -  Event of angina or AMI, at any time, whether I've done some examination or not;&#xD;
&#xD;
          -  Finger tip blood glucose &lt; 70 and &gt; 200mg/dL at the time of examination;&#xD;
&#xD;
          -  Chest injury &gt; 50%;&#xD;
&#xD;
          -  Triple arterial injury with surgery indication;&#xD;
&#xD;
          -  Moderate or severe chronic obstructive pulmonary disease (COPD) confirmed by&#xD;
             spirometry;&#xD;
&#xD;
          -  Pulmonary hypertension with pressure &gt; 35mmHg confirmed by doppler echocardiography;&#xD;
&#xD;
          -  Moderate or important aortic and/or mitral valvulopathy confirmed by doppler&#xD;
             echocardiography;&#xD;
&#xD;
          -  Changes in enzyme markers (Troponin I) after the first test;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Franken, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade da Santa Casa de Misericórdia de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jorge Barros Afiune</name_title>
    <organization>Cristália Pordutos Químicos Farmacêuticos Ltda</organization>
  </responsible_party>
  <keyword>Coronaropathy</keyword>
  <keyword>lodenafil carbonate</keyword>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Treatment</keyword>
  <keyword>QT interval</keyword>
  <keyword>Phosphodiesterase inhibitors</keyword>
  <keyword>Cardiac arrhythmia</keyword>
  <keyword>Effort testPhosphodiesterase 5 inhibitors</keyword>
  <keyword>Cardiovascular test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

